May 18, 2021
Camlin Fine Sciences will be acquiring 80% stake in AlgalR NutraPharms. The Company will now be executing the Investment Agreement, Share Purchase Agreement, and the incidental agreements/documents with AlgalR and its promoters / other shareholders.
AlgalR provides an opportunity to the Company for expanding its footprint into the Nutraceuticals segment.
AlgalR was incorporated on 24 July 2014.
It is a manufacturer of Algal Omega]3 fatty acids, particularly Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) from microalgae, which are considered 100% Vegetarian. Omega3 fatty acids play an important role in human metabolism and have been associated with a number of health benefits. These products are manufactured in compliance with the set industrial norms, FSSAI, and ISO 22000:2005 standards using patented technology in a state]of]the]art production system located in the Southern part of India.